Triptans and CGRP blockade: impact on the cranial vasculature
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Triptans and CGRP blockade : impact on the cranial vasculature. / Benemei, Silvia; Cortese, Francesca; Labastida-Ramírez, Alejandro; Marchese, Francesca; Pellesi, Lanfranco; Romoli, Michele; Vollesen, Anne Luise; Lampl, Christian; Ashina, Messoud; School of Advanced Studies of the European Headache Federation (EHF-SAS).
I: Journal of Headache and Pain, Bind 18, 103, 10.10.2017.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Triptans and CGRP blockade
T2 - impact on the cranial vasculature
AU - Benemei, Silvia
AU - Cortese, Francesca
AU - Labastida-Ramírez, Alejandro
AU - Marchese, Francesca
AU - Pellesi, Lanfranco
AU - Romoli, Michele
AU - Vollesen, Anne Luise
AU - Lampl, Christian
AU - Ashina, Messoud
AU - School of Advanced Studies of the European Headache Federation (EHF-SAS)
PY - 2017/10/10
Y1 - 2017/10/10
N2 - The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.
AB - The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.
KW - Journal Article
KW - Review
U2 - 10.1186/s10194-017-0811-5
DO - 10.1186/s10194-017-0811-5
M3 - Review
C2 - 29019093
VL - 18
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
SN - 1129-2369
M1 - 103
ER -
ID: 186152362